Funding Opportunities

Current funding opportunities related to TB and HIV, expired RFAs will be hidden after closing date. Sort using the tags menu to the right.

For funding opportunities related to global health, please see the Vanderbilt Institute for Global Health announcements found here.

Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)

Open Date (Earliest Submission Date): April 07, 2025
Expiration Date: January 08, 2028

Funds Available and Anticipated Number of Awards

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Award Budget

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 in direct costs may be requested in any single year.

Award Project Period

The total project period may not exceed 2 years.

Additional details about the R21 can be found here.

Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)

Open Date (Earliest Submission Date): April 07, 2025
Expiration Date: January 08, 2028

Funds Available and Anticipated Number of Awards

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

This NOFO is soliciting R01 applications that support a discrete, specified, circumscribed project (up to 5 years) to be performed by the named investigator(s) in an area representing the investigator's specific interest and competencies. The companion R21 NOFO (PAR-25-316) will support shorter term (up to 2 years) exploratory/developmental research activities. All R01 applications should provide preliminary data to support hypotheses and/or justify any descriptive studies. 

Award Budget

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Award Project Period

The scope of the proposed project should determine the project period. The maximum project period is five years.

Additional details about the R01 can be found here.

Applications Now Open The RePORT International Coordinating Center (RICC) Post-Doctoral Fellowship Program

Applications are now being accepted for the RePORT International Coordinating Center (RICC) Post-doctoral Fellowship. The deadline for applications is Friday, January 31, 2025.

Eligibility Criteria 

 

  • A graduate degree (e.g., MD and/or PhD)  

  • Currently employed or a student at one of the RePORT partner institutions in Brazil, China, India, Indonesia, Philippines, South Africa, South Korea, or Uganda  

  • Institutional mechanism to receive and manage the funding of their stipend 

  • Less than 10 years of experience since the end of their most recent graduate degree (MD or PhD) 

  • Interest in a TB research career 

Fellowship Support 

 

Fellows will be selected in April 2025 and this program will include:  

 

  • A $25,000 stipend for the Fellow per year for two years (Total $50,000)

  • Specific online courses and webinars focused on developing TB research competencies 

  • Access to strategic technical support consultations, including data management, biostatistics, research ethics, study design, implementation science and community engagement from RICC experts to support the development of their research proposal 

  • Frequent opportunities to present research proposals to other fellows, mentors and experts for advice and feedback 

  • Support for 5% of the fellows’ faculty mentors’ time full-time effort (FTE) for up to two years.   

 

Click on the link at the top of the page for additional details about this program.

 

Please share this announcement with any early-stage investigators that you feel would be interested in applying for this unique opportunity. 

Pre-Application Information and Questions: 

For questions about this program please email Dr. Bob Bollinger (rcb@jhmi.edu) or Mary Talalay (mtalalay@jhu.edu). 

 

For Additional Information: 

 

  • To apply to this program, please click here. Deadline for submission is January 31, 2025. 

  • For an overview of RICC, please click here.  

  • For fiscal questions related to mentor FTE or fellow stipend support please contact Audrey Mioli (aik5@njms.rutgers.edu) or Lorraine Luciano-McKeon (lucianlo@njms.rutgers.edu) 

  • All other questions related to this program should be communicated to the RICC CSWG c/o Mary Talalay (mtalalay@jhu.edu) and Dr. Bob Bollinger (rcb@jhmi.edu) 

Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed) Expires: March 14, 2025

Open Date (Earliest Submission Date): February 13, 2025

Expiration Date: March 14, 2025

Funds Available and Anticipated Number of Awards
NIAID intends to commit an estimated total of $4,000,000 in FY 2026 to fund 3-5 awards.

Award Budget
Application budgets are not expected to exceed $700,000 in direct costs less consortium indirect (F&A) per year during the R61 Phase and $1,000,000 in direct costs less consortium indirect (F&A) per year during the R33 Phase. Requested budgets should reflect the actual needs of the proposed project.

Award Project Period
Applicants may request up to two years of support for the R61 phase, and up to three years of support for the R33 phase. The maximum project period for an application submitted in response to this NOFO cannot exceed five years total.

 

Find additional information here

Halting Tuberculosis (TB) Transmission (R01 Clinical Trial Optional), Expires: December 05, 2024

Open Date (Earliest Submission Date): November 04, 2024

Expiration Date: December 05, 2024

Funds Available and Anticipated Number of Awards
NIAID intends to commit $6,000,000 in FY 2025 to fund 4-5 awards.

Award Budget
Application budgets are not expected to exceed $750,000 in direct costs per year, and should reflect the actual needs of the project. 

Award Project Period
The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Find additional information here
 

Tags

CRDFGlobal RFP Announced: Cross Consortium Funding for the RePORT International Consortium

The RePORT International Coordinating Center (RICC) invites researchers to submit full proposals for the Cross Consortium Funding for the RePORT International Consortium. This initiative will provide a maximum of two (2) years of funding to support two (2) to three (3) projects to support the development of collaborations across the RePORT consortium. This competition is organized by the RICC and administered by CRDF Global on behalf of the National Institute of Allergies and Infectious Diseases (NIAID).   

Full proposals must be submitted to CRDF Global’s Cross Consortium intake inbox Cross-Consortium@crdfglobal.org no later than Friday, June 21, 2024 (23:59) U.S. Eastern Standard Time (EST). Proposals will undergo a round of peer evaluation. 

Please visit CRDF Global’s website to view the request for proposals for more information by following this link: https://www.crdfglobal.org/rfp/cross-consortium-funding-for-the-report-international-consortium/

TB Elimination Alliance Announces 2023 Mini-Grant Program Awardees

The Tuberculosis Elimination Alliance (TEA), led by the Association of Asian Pacific Community Health Organizations (AAPCHO), Asian & Pacific Islander American Health Forum (APIAHF), Hepatitis B Foundation (HBF), and Stop TB USA, with the support of the Centers for Disease Control and Prevention’s (CDC) Division of TB Elimination, announced that it awarded a total of $250,000 to 12 community health organizations serving Asian, Asian American (A/AA), Native Hawaiian, and Pacific Islander (NH/PI), Hispanic/Latino and African American communities that are disproportionately impacted by tuberculosis (TB).

 

TEA offered a third cycle of 12 mini-grant awards totaling $250,000 to community providers that increase awareness and build capacity on TB testing and treatment. The newly awarded mini-grant recipients in this cycle are as follows:

  • Arkansas Coalition of Marshallese (Springdale, AR)
  • Asian Pacific Health Foundation (San Diego, CA)
  • EthnoMed (Seattle, WA)
  • Jericho Road Community Health Center (Buffalo, NY)
  • Midwest Asian Health Association (Chicago, IL)
  • Mission Neighborhood Health Center (San Francisco, CA)
  • Regional Pacific Islander Taskforce (San Francisco, CA)
  • Revive Community Health (Tempe, AZ)
  • Rural Women's Health Project (Gainesville, FL)
  • San Diego County Medical Society Foundation, dba Champions for Health (San Diego, CA)
  • Todu Guam Foundation, Ltd. (Tamuning, Guam)
  • We Are TB / Somos TB (National)

Since its inception in 2019, TEA has distributed over $800,000 in mini-grant funding to 36 organizations. TEA, our members, partners, and mini-grantees look forward to building on the progress that we have made so far towards TB elimination. 

For more information on TEA, please visit www.tbeliminationalliance.org.

Tags

Notice of Special Interest (NOSI): Advancing Biomedical Research in Pulmonary Non-Tuberculous Mycobacterial (NTM) Infections

Open Date (Earliest Submission Date): October 05, 2023

Expiration Date: July 17, 2026

This Notice of Special Interest (NOSI) encourages applications that seek to better understand Pulmonary Non-Tuberculous Mycobacteria (NTM) Infections and inform development of medical countermeasures. This NOSI aims to stimulate advances in diagnosis and treatment of NTM infections that cause or exacerbate pulmonary disease such as Mycobacterium abscessus, Mycobacterium avium complex, and Mycobacterium kansasii.

For more information, click here

Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 - Clinical Trial Not Allowed) expires 10/12/2023

Due Dates: October 11, 2023

Open Date: Earliest Submission Date: September 11, 2023

The purpose of this Notice of Funding Opportunity (NOFO) is to support mechanistic studies of the early stage of Mycobacterium tuberculosis (Mtb) infection, with and without HIV, to identify interventional targets for vaccine and host-directed therapies. This Notice of Funding Opportunity (NOFO) will support mechanistic studies of early Mtb infection (defined as the time between Mtb exposure and early-stage granuloma formation) in the airway and lung with the ultimate goal of understanding these events in the setting of HIV co-infection.   

More information here

Tags
RSS: